Oncocyte Corp Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Oncocyte Corp has filed its Q1 2024 10-Q report, detailing financial performance and corporate information.</b>

AI Summary

Oncocyte Corp (IMDX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Oncocyte Corp filed a 10-Q report for the period ending March 31, 2024. The filing details financial information for the first quarter of 2024. Key dates include the filing date of May 15, 2024, and the period of report as March 31, 2024. The company's principal business address is 15 Cushing, Irvine, CA 92618. Oncocyte Corp was formerly known as OncoCyte Corp and Oncocyte Corp.

Why It Matters

For investors and stakeholders tracking Oncocyte Corp, this filing contains several important signals. This 10-Q filing provides investors with the latest quarterly financial data, enabling them to assess the company's performance and make informed investment decisions. Understanding the details within this report is crucial for tracking Oncocyte Corp's financial health, operational progress, and any significant developments since the last filing.

Risk Assessment

Risk Level: low — Oncocyte Corp shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate indicators of significant new risks or opportunities.

Analyst Insight

Review the detailed financial statements and any new disclosures in the 10-Q to understand Oncocyte Corp's current financial position and operational status.

Key Numbers

• 2024-03-31 — Period End Date (Conformed period of report)
• 2024-05-15 — Filing Date (Filed as of date)
• 2024-01-01 — Quarter Start Date (Reporting period)
• 2023-12-31 — Previous Year End Date (Balance sheet date)

Key Players & Entities

• Oncocyte Corp (company) — Filer name
• 2024-03-31 (date) — Conformed period of report
• 2024-05-15 (date) — Filed as of date
• 15 Cushing (address) — Business address street 1
• Irvine (location) — Business address city
• CA (location) — Business address state
• 92618 (postal_code) — Business address zip
• 949-409-7600 (phone_number) — Business phone

FAQ

Industry Context

Oncocyte Corp operates in the in vitro and in vivo diagnostic substances industry, focusing on developing and commercializing diagnostic tests.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the financial statements within the 10-Q for revenue, expenses, and cash flow.
2. Review any new risk factors or legal proceedings disclosed in the filing.
3. Compare the current quarter's performance to previous periods and industry benchmarks.

Key Dates

• 2024-05-15: 10-Q Filing — Filing of the quarterly report for the period ending March 31, 2024.
• 2024-03-31: Reporting Period End — End date for the financial information presented in the 10-Q.
• 2024-01-01: Reporting Period Start — Start date for the financial information presented in the 10-Q.

Year-Over-Year Comparison

This filing represents the first quarterly report for Oncocyte Corp in 2024, providing updated financial and operational information compared to the previous year's filings.

Filing Documents

• form10-q.htm (10-Q) — 1505KB
• ex10-6.htm (EX-10.6) — 266KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 9KB
• 0001493152-24-019842.txt (&nbsp;) — 9077KB
• ocx-20240331.xsd (EX-101.SCH) — 58KB
• ocx-20240331_cal.xml (EX-101.CAL) — 73KB
• ocx-20240331_def.xml (EX-101.DEF) — 342KB
• ocx-20240331_lab.xml (EX-101.LAB) — 486KB
• ocx-20240331_pre.xml (EX-101.PRE) — 440KB
• form10-q_htm.xml (XML) — 1564KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 42

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 53

Controls and Procedures

Item 4. Controls and Procedures 53

- OTHER INFORMATION

PART II - OTHER INFORMATION 54

Legal Proceedings

Item 1. Legal Proceedings 54

Risk Factors

Item 1A. Risk Factors 54

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 54

Default Upon Senior Securities

Item 3. Default Upon Senior Securities 54

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 54

Other Information

Item 5. Other Information 54

Exhibits

Item 6. Exhibits 55

SIGNATURES

SIGNATURES 56 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would") should also be considered to be forward-looking statements. Forward-looking of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking those mentioned in this Report under Item 1 of the Notes to Consolidated Financial Statements, under Risk Factors in this Report and those Risk Factors in Part I, Item 1A of our most recent Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission ("SEC"). Except as required by law, Oncocyte undertakes no obligation to update any

forward-looking statements to reflect events or circumstances after the date of such statements

forward-looking statements to reflect events or circumstances after the date of such statements. The

forward-looking statements include, among other things, statements about

forward-looking statements include, among other things, statements about: the timing and potential achievement of future milestones; the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers; our plans to pursue research and development of diagnostic test candidates; the potential commercialization of diagnostic tests currently in development; the timing and success of future clinical research and the period during which the results of the clinical research will become available; the potential receipt of revenue from current sales of our diagnostic tests and/or diagnostic tests in development; our assumptions regarding obtaining reimbursement and reimbursement rates of our current diagnostic tests and/or diagnostic tests in development; our estimates regarding future orders of tests and our ability to perform a projected number of tests; our estimates and assumptions around the patient populations, market size and price points for reimbursement for our diagnostic tests our estimates regarding future revenues, operating expenses, and future capital requirements; our intellectual property position; the impact of government laws and regulations; and our competitive position. Unless the context otherwise requires, all references to "Oncocyte," "we," "us," "our," "the Company" or similar words refer to Oncocyte Corporation, together with our consolidated subsidiaries. The description or discussion, in this Report, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement. DetermaIO, DetermaCNI, and VitaGraft are trademarks of Oncocyte, regardless of whether the "TM" symbol accompanies the use of or reference to the applicable trademark in this Report. 3 PART 1—FINANCIAL INFORMATION Item 1. Financial Statements. ONCOCYTE CORPORATION CONDENSE

View Full Filing

View this 10-Q filing on SEC EDGAR